Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis

Fig. 4

MiR-103a-3p inhibits the Hippo pathway by directly targeting LATS2 and SAV1. a-b The mRNA levels of the core molecules of the Hippo pathway were detected in HCT116 and SW480 cells transfected with vector-1, sh-miR-103a-3p, vector-2, or miR-103a-3p mimics. c Venn diagrams exhibiting the shared targets of miR-103a-3p predicted from the TargetScan, miRDB, Tarbase and PITA databases. d Scheme of the potential binding sites of miR-103a-3p in the LATS2/SAV1 3′UTR. Luciferase assay in 293 T cells e and HCT116 cells f. MiR-103a-3p mimics or mimic controls were cotransfected with pReporter-LATS2(SAV1)-WT (wild type) 3′UTR or pReporter-LATS2(SAV1)-MT (mutant type) 3′UTR. Luciferase activity was decreased in the pReporter-LATS2(SAV1)-WT group. g The levels of LATS2 and SAV1 were determined in tumour tissues from miR-103a-3p antagomir group and control group by qRT-PCR. *p < 0.05, **p < 0.01

Back to article page